Hochhaus, A
Masszi, T
Giles, F J
Radich, J P
Ross, D M
Gómez Casares, M T
Hellmann, A
Stentoft, J
Conneally, E
García-Gutiérrez, V
Gattermann, N
Wiktor-Jedrzejczak, W
le Coutre, P D
Martino, B
Saussele, S
Menssen, H D
Deng, W
Krunic, N
Bedoucha, V
Saglio, G
Article History
Received: 12 December 2016
Revised: 19 January 2017
Accepted: 2 February 2017
First Online: 20 February 2017
Competing interests
: The authors declare the following relationships: A Hochhaus: reports honoraria from Novartis, BMS, ARIAD and Pfizer; consulting or advisory role for Novartis, BMS, ARIAD and Pfizer; research funding from Novartis, BMS, ARIAD, Pfizer and MSD; travel, accommodation or other expenses paid or reimbursed by Novartis and BMS; T Masszi: reports honoraria from Novartis, Takeda, Janssen-Cilag and BMS; consulting or advisory role for Novartis, Takeda, Janssen-Cilag and BMS; FJ Giles: reports honoraria from Novartis; consulting or advisory role for Novartis; research funding from Novartis; JP Radich: reports consulting or advisory role for Novartis, ARIAD, BMS and Gilead; research funding from Novartis; DM Ross: reports honoraria from Novartis and BMS; consulting or advisory role for Novartis; research funding from Novartis and Celgene; MT Gómez Casares: reports honoraria from BMS, Novarti, and ARIAD; consulting or advisory role for BMS, Novartis and ARIAD; travel, accommodation or other expenses paid or reimbursed by BMS, Novartis and ARIAD; A Hellmann: reports honoraria from Novartis, BMS and ARIAD; travel, accommodation, or other expenses paid or reimbursed by Novartis, Orphan, Servier and BMD; J Stentoft: reports research funding from Novartis, BMS, Pfizer and ARIAD; E Conneally: reports honoraria from Novartis, BMS, Pfizer and Gilead; consulting or advisory role for Novartis, BMS, Pfizer and Gilead; research funding from BMS and Pfizer; V García-Gutiérrez: reports honoraria from Novartis, BMS, Pfizer and ARIAD; consulting or advisory role for Novartis, BMS, Pfizer and ARIAD; research funding from Novartis, BMS, Pfizer and ARIAD; travel, accommodation, or other expenses paid or reimbursed by Novartis, BMS, Pfizer and ARIAD; N Gattermann: reports honoraria, research funding and travel, accommodation, or other expenses paid or reimbursed by Novartis; W Wiktor-Jedrzejczak: reports consulting or advisory role for Roche, Janssen-Cilag, Onconova, Celgene, Sandoz and Angelini; research funding from Amgen, BMS, Novartis and AbbVie; expert testimony for Celgene; travel, accommodation or other expenses paid or reimbursed by Pierre Fabre, Novartis, Roche and Sanofi; PD le Coutre: reports participation in a speakers bureau for Novartis, BMS, Pfizer and ARIAD; B Martino: has nothing to disclose; S Saussele: reports honoraria from Novartis, BMS, Pfizer and ARIAD; consulting or advisory role for Novartis, BMS, Pfizer and ARIAD; research funding from Novartis and BMS; travel, accommodation or other expenses paid or reimbursed by Novartis and BMS; HD Menssen: is employed by, and owns stock in, Novartis Pharma AG; W Deng: is employed by Novartis Pharmaceuticals Corporation; N Krunic: is employed by, and owns stock in, Novartis Institute for Biomedical Research; V Bedoucha: is employed by Novartis Pharma AG; G Saglio: reports consulting or advisory role for Novartis, BMS, ARIAD, and Pfizer.